« Primary Endpoint Data from Phase I Part B | Main | Equity Financing »
Tuesday
Apr052016

Completion of enrolment of Phase I Part B

MinervaX announces that it today has enrolled and dosed the last of 240 subjects in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN.